Barclays PLC Vaxxinity, Inc. Transaction History

Barclays PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.05 - $0.71 $1,491 - $21,181	-29,833 Reduced 99.99%	2 $0
Q1 2024 May 15, 2024	SELL	$0.62 - $0.86 $17,767 - $24,645	-28,657 Reduced 48.99%	29,835 $21,000
Q4 2023 Feb 15, 2024	BUY	$0.7 - $1.31 $35,488 - $66,414	50,698 Added 650.47%	58,492 $49,000
Q3 2023 Nov 07, 2023	SELL	$1.25 - $3.0 $1,046 - $2,511	-837 Reduced 9.7%	7,794 $10,000
Q2 2023 Aug 03, 2023	BUY	$1.73 - $2.79 $14,931 - $24,080	8,631 New	8,631 $22,000

198K

Ticker VAXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 112,150,000
Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.